A109 PREGNANCY OUTCOMES IN WOMEN EXPOSED TO USTEKINUMAB IN THE CROHN’S DISEASE CLINICAL DEVELOPMENT PROGRAM

BACKGROUND: Ustekinumab (UST) has been approved for moderate to severe Crohn’s Disease (CD) in adult patients (pts). While no adverse developmental outcomes (pre-& postnatal) were observed in animal studies of UST, limited data exist, including previously reported outcomes in psoriasis (PsO) pts...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Can Assoc Gastroenterol
Autores principales: Scherl, E, Jacobstein, D, Murphy, C, Ott, E, Gasink, C, Baumgart, D C, Abraham, B
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Paper Sessions
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508401/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.109
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares